Yesterday's NYT science section had an article about Sirtris Pharmaceuticals (recently purchased by GlaxoSmithKline). Sirtris has been working to develop resveratrol-related compounds to treat diseases like diabetes, using methods that generated interest because they seem to have extend the lives of mice by about %30.
Yup, talk about burying the lede! As you read the article, you'll see that the drug developers have to practically disown the goal of extending life years in healthy people, while embracing the notion that the drugs they are developing can treat traditional diseases. It's probably not their fault; in order to get FDA-approval, they need to identify some traditional disease that is treated by their product. Apparently, the disease of aging doesn't qualify. I say, increase lifespan and healthspan. Here's an excerpt:
The impact of Sirtris’s drugs, if successful, could extend beyond the drug industry. Dr. Guarente believes that many people might start taking them in middle age, though after having started a family because they may suppress fertility.
Mice on the drugs generally remain healthy right until the end of their lives and then just drop dead.“If they work in people that way, one would look to an extension of health span, with an extension of life as a possible side effect,” Dr. Guarente said. “It would necessitate changing ideas about when people retire and when they stop paying into the system.”
GlaxoSmithKline could put SRT501, its resveratrol formulation, on the market right away, selling it as a natural compound and nutritional pharmaceutical that does not require approval by the F.D.A. “We haven’t made any decisions, but that clearly is an option,” Dr. Vallance said.
I'll be very interested to see how GlaxoSmithKline handles this last issue. If SRT501 works as some say it does, might the anti-enhancement forces still rule the day?